NCT05533242 - Radioimmunotherapy with Lu-177 Labeled 6A10 Fab-fragments in Patients with Glioblastoma After Standard Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Glioblastom WHO Grade 4

Interventions

DRUG

Lu-177 labeled 6A10-Fab-fragments

The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.

Trial Locations (7)

45147

RECRUITING

Klinik für Neurochirurgie des Universitätsklinikums Essen, Essen

RECRUITING

Klinik für Nuklearmedizin, Strahlenklinik des Universitätsklinikums Essen, Essen

48149

RECRUITING

Klinik für Nuklearmedizin der Universität Münster, Münster

50937

RECRUITING

Klinik für Allgemeine Neurochirurgie des Universitätsklinikums Köln, Cologne

RECRUITING

Klinik für Nuklearmedizin des Universitätsklinikums Köln, Cologne

97080

RECRUITING

Universitätsklinikum Würzburg - Neurochirurgie, Würzburg

RECRUITING

Universitätsklinikum Würzburg - Nuklearmedizin, Würzburg